Nothing Special   »   [go: up one dir, main page]

MX2013004464A - Inhibidores de polimerasa viral. - Google Patents

Inhibidores de polimerasa viral.

Info

Publication number
MX2013004464A
MX2013004464A MX2013004464A MX2013004464A MX2013004464A MX 2013004464 A MX2013004464 A MX 2013004464A MX 2013004464 A MX2013004464 A MX 2013004464A MX 2013004464 A MX2013004464 A MX 2013004464A MX 2013004464 A MX2013004464 A MX 2013004464A
Authority
MX
Mexico
Prior art keywords
polymerase inhibitors
viral polymerase
infections
viral
hcv
Prior art date
Application number
MX2013004464A
Other languages
English (en)
Inventor
Rosliana Halim
Michael Harding
Richard Hufton
Craig James Morton
Saba Jahangiri
Brett Raymond Pool
Tyrone Pieter Jeynes
Alistair George Draffan
Michael John Lilly
Barbara Frey
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of MX2013004464A publication Critical patent/MX2013004464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con inhibidores de polimerasa viral de fórmula (I), sales, N-óxidos, solvatos, hidratos, racematos, enantiómeros e isómeros de los mismos, procesos para su preparación y su uso en el tratamiento de infecciones virales por Flaviviridae tales como infecciones por el virus de hepatitis C (HCV): (Ver Formula).
MX2013004464A 2010-10-20 2011-10-20 Inhibidores de polimerasa viral. MX2013004464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39499410P 2010-10-20 2010-10-20
PCT/AU2011/001336 WO2012051659A1 (en) 2010-10-20 2011-10-20 Viral polymerase inhibitors

Publications (1)

Publication Number Publication Date
MX2013004464A true MX2013004464A (es) 2013-07-12

Family

ID=45974556

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004464A MX2013004464A (es) 2010-10-20 2011-10-20 Inhibidores de polimerasa viral.

Country Status (15)

Country Link
US (1) US8546389B2 (es)
EP (1) EP2630128A4 (es)
JP (1) JP5826856B2 (es)
KR (1) KR20140023256A (es)
CN (1) CN103298791B (es)
AU (1) AU2011318241A1 (es)
BR (1) BR112013009461A2 (es)
CA (1) CA2815055A1 (es)
EA (1) EA201300473A1 (es)
IL (1) IL225861A (es)
MX (1) MX2013004464A (es)
NZ (1) NZ610331A (es)
SG (1) SG189882A1 (es)
WO (1) WO2012051659A1 (es)
ZA (1) ZA201303410B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785478B2 (en) 2012-04-11 2014-07-22 Biota Scientific Management Pty Ltd. Viral polymerase inhibitors
EP2935250B1 (en) 2012-12-17 2018-03-28 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
WO2014097152A1 (en) * 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
US20220081433A1 (en) * 2018-09-05 2022-03-17 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv
US20230075856A1 (en) * 2018-09-05 2023-03-09 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0991625B1 (en) * 1997-06-19 2005-06-01 Bristol-Myers Squibb Pharma Company Inhibitors of factor xa with a neutral p1 specificity group
UA79834C2 (en) 2002-11-01 2007-07-25 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005014543A1 (ja) * 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) * 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2408448A4 (en) * 2009-03-18 2012-09-19 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
CN102906089A (zh) * 2010-03-10 2013-01-30 百时美施贵宝公司 用于治疗丙型肝炎的化合物

Also Published As

Publication number Publication date
JP5826856B2 (ja) 2015-12-02
EP2630128A1 (en) 2013-08-28
CN103298791B (zh) 2016-02-03
IL225861A0 (en) 2013-09-30
BR112013009461A2 (pt) 2016-07-12
SG189882A1 (en) 2013-06-28
US8546389B2 (en) 2013-10-01
EA201300473A1 (ru) 2013-09-30
NZ610331A (en) 2015-01-30
AU2011318241A1 (en) 2013-05-30
EP2630128A4 (en) 2013-08-28
WO2012051659A1 (en) 2012-04-26
CA2815055A1 (en) 2012-04-26
KR20140023256A (ko) 2014-02-26
US20120142686A1 (en) 2012-06-07
ZA201303410B (en) 2014-03-26
JP2013540134A (ja) 2013-10-31
CN103298791A (zh) 2013-09-11
IL225861A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
EP2542545A4 (en) INHIBITORS OF HEPATITIS C-VIRUS NS5B POLYMERASE
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
WO2013074386A3 (en) Hcv ns3 protease inhibitors
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012000959A (es) Inhibidores de los virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
EP2600835A4 (en) COMBINATIONS OF INHIBITORS OF HEPATITIS C VIRUS
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
TN2011000475A1 (en) Inhibitors of hepatitis c virus replication
NZ603310A (en) Heterocyclic flaviviridae virus inhibitors
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
SI2209789T1 (sl) Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2012002925A (es) Inhibidores de virus flaviviridae.
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
EA201391717A1 (ru) Ингибиторы вируса гепатита с
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
MX2013004464A (es) Inhibidores de polimerasa viral.
WO2014123795A3 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
MX2013012771A (es) Proceso para la preparacion de inhibidores del virus de la hepatitis c.
BR112013000245A2 (pt) compostos antivirais heterocíclicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal